New Human Gene Therapy editorial: Concern following gene therapy adverse events

(Mary Ann Liebert, Inc./Genetic Engineering News) Response to the recent report of the deaths of two children receiving high doses of a gene therapy vector (AAV8) in a Phase I trial for X-linked myotubular myopathy (MTM). The news "is a tragic reminder of how difficult it is to predict outcomes in first-in-human studies